Display options
Cite
Keswani AN, Williams C, Fuloria J, et al. Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J. 2015;15(2):187-90
Keswani, A. N., Williams, C., Fuloria, J., Polin, N. M., & Jahangir, E. (2015). Rituximab-Induced Acute ST Elevation Myocardial Infarction. The Ochsner journal, 15(2), 187-90.
Keswani, Amit N, et al. "Rituximab-Induced Acute ST Elevation Myocardial Infarction." The Ochsner journal vol. 15,2 (2015): 187-90.
Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E. Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J. 2015;15(2):187-90. PMID: 26130984; PMCID: PMC4482563.
Copy Download .nbib Format: NLM
Share it on

Ochsner J. 2015;15(2):187-90.

Rituximab-Induced Acute ST Elevation Myocardial Infarction.

The Ochsner journal

Amit N Keswani, Cody Williams, Jyotsna Fuloria, Nichole M Polin, Eiman Jahangir

Affiliations

  1. The John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, New Orleans, LA.
  2. Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA.
  3. Department of Hematology and Oncology, Ochsner Clinic Foundation, New Orleans, LA.
  4. The John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, New Orleans, LA ; The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA.

PMID: 26130984 PMCID: PMC4482563

Abstract

BACKGROUND: Rituximab has rarely been associated with acute coronary syndrome (ACS). We report the case of a patient in whom rituximab, a monoclonal antibody used to treat lymphomas of B-cell origin, induced ST elevation myocardial infarction.

CASE REPORT: A 46-year-old male patient diagnosed with stage II non-Hodgkin lymphoma presented to the emergency department with acute crushing, substernal chest pain that radiated to his back 1 day after a chemotherapy infusion with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. An electrocardiogram revealed normal sinus rhythm with ST elevations in the inferior leads. The patient underwent primary percutaneous coronary intervention (PCI) of his right coronary artery and first diagonal artery with placement of drug-eluting stents. He did well postprocedure and resumed therapy with rituximab under close monitoring by the cardiology and oncology departments without any further cardiac events.

CONCLUSION: In patients with ACS because of chemotherapy, complete revascularization during PCI should be considered.

Keywords: Acute coronary syndrome; lymphoma–non-Hodgkin; myocardial infarction; percutaneous coronary intervention; rituximab

References

  1. Tex Heart Inst J. 2014 Feb;41(1):80-2 - PubMed
  2. Am Heart J. 2014 Jan;167(1):1-14.e2 - PubMed
  3. J Am Coll Cardiol. 2011 Aug 9;58(7):692-703 - PubMed
  4. Toxicol Sci. 2010 Sep;117(1):144-51 - PubMed
  5. G Ital Cardiol. 1985 Jan;15(1):107-11 - PubMed
  6. J Clin Oncol. 2011 Jan 10;29(2):174-85 - PubMed
  7. Cancer. 1975 Dec;36(6):1979-82 - PubMed
  8. Clin Lymphoma Myeloma. 2008 Aug;8(4):253-5 - PubMed

Publication Types